These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36409315)

  • 21. Development of attributes and attribute levels for a discrete choice experiment on patients' and providers' choice for antiretroviral therapy service in Northwest Ethiopia.
    Belay YA; Yitayal M; Atnafu A; Taye FA
    AIDS Res Ther; 2023 Jun; 20(1):33. PubMed ID: 37271808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis along the continuum of HIV care: how can we optimize the effect of HIV treatment as prevention programs?
    Nosyk B; Krebs E; Eyawo O; Min JE; Barrios R; Montaner JS
    Curr HIV/AIDS Rep; 2014 Dec; 11(4):468-78. PubMed ID: 25173799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Divergent Preferences for HIV Prevention: A Discrete Choice Experiment for Multipurpose HIV Prevention Products in South Africa.
    Quaife M; Eakle R; Cabrera Escobar MA; Vickerman P; Kilbourne-Brook M; Mvundura M; Delany-Moretlwe S; Terris-Prestholt F
    Med Decis Making; 2018 Jan; 38(1):120-133. PubMed ID: 28863752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring perceptions of using preference elicitation methods to inform clinical trial design in rheumatology: A qualitative study and OMERACT collaboration.
    Thomas M; Marshall DA; Sanchez AL; Bartlett SJ; Boonen A; Fraenkel L; Proulx L; Voshaar M; Bansback N; Buchbinder R; Guillemin F; Hiligsmann M; Richards DP; Richards P; Shea B; Tugwell P; Falahee M; Hazlewood GS
    Semin Arthritis Rheum; 2023 Feb; 58():152112. PubMed ID: 36372015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A modelling framework for translating discrete choice experiment results into cost-effectiveness estimates: an application to designing tailored and scalable HIV and contraceptive services for adolescents in Gauteng, South Africa.
    Govathson C; Long LC; Russell CA; Moolla A; Pascoe S; Nichols BE
    J Int AIDS Soc; 2023 Jul; 26(7):e26124. PubMed ID: 37463870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of NIH in the Ending the HIV Epidemic in the US Initiative: Research Improving Practice.
    Glenshaw MT; Gaist P; Wilson A; Cregg RC; Holtz TH; Goodenow MM
    J Acquir Immune Defic Syndr; 2022 Jul; 90(S1):S9-S16. PubMed ID: 35703750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using Digital Communication Technology to Increase HIV Testing Among Men Who Have Sex With Men and Transgender Women: Systematic Review and Meta-Analysis.
    Veronese V; Ryan KE; Hughes C; Lim MS; Pedrana A; Stoové M
    J Med Internet Res; 2020 Jul; 22(7):e14230. PubMed ID: 32720902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methods for Conducting Stated Preference Research with Children and Adolescents in Health: A Scoping Review of the Application of Discrete Choice Experiments.
    Michaels-Igbokwe C; Currie GR; Kennedy BL; MacDonald KV; Marshall DA
    Patient; 2021 Nov; 14(6):741-758. PubMed ID: 34008164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two for the price of one: If moving beyond traditional single-best discrete choice experiments, should we use best-worst, best-best or ranking for preference elicitation?
    Huls SPI; Lancsar E; Donkers B; Ride J
    Health Econ; 2022 Dec; 31(12):2630-2647. PubMed ID: 36102864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How much demand for New HIV prevention technologies can we really expect? Results from a discrete choice experiment in South Africa.
    Terris-Prestholt F; Hanson K; MacPhail C; Vickerman P; Rees H; Watts C
    PLoS One; 2013; 8(12):e83193. PubMed ID: 24386160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identifying and Prioritizing Implementation Barriers, Gaps, and Strategies Through the Nigeria Implementation Science Alliance: Getting to Zero in the Prevention of Mother-to-Child Transmission of HIV.
    Ezeanolue EE; Powell BJ; Patel D; Olutola A; Obiefune M; Dakum P; Okonkwo P; Gobir B; Akinmurele T; Nwandu A; Torpey K; Oyeledum B; Aina M; Eyo A; Oleribe O; Ibanga I; Oko J; Anyaike C; Idoko J; Aliyu MH; Sturke R; Watts H; Siberry G;
    J Acquir Immune Defic Syndr; 2016 Aug; 72 Suppl 2(Suppl 2):S161-6. PubMed ID: 27355504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A discrete choice experiment to assess patients' preferences for HIV treatment in the rural population in Colombia.
    Goossens AJM; Cheung KL; Sijstermans E; Conde R; Gonzalez JGR; Hiligsmann M
    J Med Econ; 2020 Aug; 23(8):803-811. PubMed ID: 32098539
    [No Abstract]   [Full Text] [Related]  

  • 33. Optimizing the engagement of care cascade: a critical step to maximize the impact of HIV treatment as prevention.
    Hull MW; Wu Z; Montaner JS
    Curr Opin HIV AIDS; 2012 Nov; 7(6):579-86. PubMed ID: 23076123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced Federal Collaborations in Implementation Science and Research of HIV Prevention and Treatment.
    Purcell DW; Namkung Lee A; Dempsey A; Gordon C
    J Acquir Immune Defic Syndr; 2022 Jul; 90(S1):S17-S22. PubMed ID: 35703751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A systematic review of early adoption of implementation science for HIV prevention or treatment in the United States.
    Shangani S; Bhaskar N; Richmond N; Operario D; van den Berg JJ
    AIDS; 2021 Feb; 35(2):177-191. PubMed ID: 33048881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimizing access to PrEP based on MSM preferences: results of a discrete choice experiment.
    Dubov A; Ogunbajo A; Altice FL; Fraenkel L
    AIDS Care; 2019 May; 31(5):545-553. PubMed ID: 30554519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantifying benefit-risk preferences for medical interventions: an overview of a growing empirical literature.
    Brett Hauber A; Fairchild AO; Reed Johnson F
    Appl Health Econ Health Policy; 2013 Aug; 11(4):319-29. PubMed ID: 23637054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Criteria for prioritization of HIV programs in Viet Nam: a discrete choice experiment.
    Safarnejad A; Pavlova M; Son VH; Phuong HL; Groot W
    BMC Health Serv Res; 2017 Nov; 17(1):719. PubMed ID: 29132355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of community-based HIV self-testing delivery strategies on reducing undiagnosed HIV infection, and improving linkage to prevention and treatment services, among men who have sex with men in Kenya: a programme science study protocol.
    Bhattacharjee P; Rego D; Musyoki H; Becker M; Pickles M; Isac S; Lorway R; Musimbi J; Walimbwa J; Olango K; Kuria S; Ongaro MK; Sahai A; Mugambi M; Emmanuel F; Mishra S; Bartilol K; Moses S; Blanchard J
    BMC Public Health; 2019 Jul; 19(1):986. PubMed ID: 31337368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of localized implementation: determining the cost-effectiveness of HIV prevention and care interventions across six United States cities.
    Krebs E; Zang X; Enns B; Min JE; Behrends CN; Del Rio C; Dombrowski JC; Feaster DJ; Gebo KA; Golden M; Marshall BDL; Metsch LR; Schackman BR; Shoptaw S; Strathdee SA; Nosyk B;
    AIDS; 2020 Mar; 34(3):447-458. PubMed ID: 31794521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.